Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT00412763 Completed - Hepatitis Clinical Trials

Efficacy of Silymarin for Acute Hepatitis

Start date: July 2003
Phase: Phase 4
Study type: Interventional

The overall objective of this project is to assess whether Silymarin therapy shortens illness or prevents complications in patients with acute hepatitis. We will specifically compare responses in acute hepatitis patients treated with Silymarin to those given a control preparation of a vitamin supplements in a double blinded, randomized, placebo-controlled trial.

NCT ID: NCT00412750 Terminated - Hepatitis B Clinical Trials

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

Start date: December 2006
Phase: Phase 3
Study type: Interventional

To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.

NCT ID: NCT00412529 Completed - Hepatitis B Clinical Trials

Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B

Start date: December 2006
Phase: Phase 3
Study type: Interventional

This exploratory study is designed to determine the early viral kinetic profile during treatment with telbivudine or entecavir at multiple time points over 12 weeks.

NCT ID: NCT00412334 Completed - Clinical trials for Hepatitis C, Chronic

SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.

Start date: January 2007
Phase: Phase 4
Study type: Interventional

This study will evaluate the efficacy and safety of 4 regimens of PEGASYS plus Copegus, in patients with chronic hepatitis C (CHC) genotype 1 who have failed to respond to previous treatment with standard doses of PEGASYS plus ribavirin. Patients will be randomized to one of 4 groups, to receive a)PEGASYS 360 micrograms/week plus Copegus 1000-1200mg/day, b)PEGASYS 180 micrograms twice weekly plus Copegus 1000-1200mg/day, c)PEGASYS 360micrograms/week plus Copegus 1200-1600mg/day, or d)PEGASYS 180 micrograms twice weekly plus Copegus 1200-1600mg/day. Following 48 weeks treatment, there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00411697 Completed - Hepatitis B Clinical Trials

Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge

Start date: December 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine at 5 years of age the persistence of immunity to hepatitis B that was conferred by infant vaccination with Infanrix hexa™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00410202 Completed - Clinical trials for Hepatitis B, Chronic

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

DEFINE
Start date: March 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine

NCT ID: NCT00410072 Completed - Clinical trials for Hepatitis B, Chronic

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

Start date: April 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. Safety will also be studied.

NCT ID: NCT00408304 Recruiting - Chronic Hepatitis C Clinical Trials

Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The purpose of the study is to check whether development of depression as a side effect of interferon alpha treatment in chronic carriers of hepatitis C can be prevented by omega-3 fatty acids.

NCT ID: NCT00407732 Completed - Hepatitis C Clinical Trials

Overcoming Psychiatric Barriers to the Treatment of Hepatitis C

Start date: January 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to develop and evaluate a 9-month psychosocial intervention that will assist patients with hepatitis C in overcoming barriers that prevent them from becoming appropriate candidates for interferon therapy.

NCT ID: NCT00403585 Completed - Chronic Hepatitis B Clinical Trials

Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814

Start date: July 2006
Phase: Phase 4
Study type: Interventional

This is an open label, single-arm, multi-centre extension study for Korean patients with chronic hepatitis B and compensated liver disease who have completed one-year adefovir dipivoxil treatment in ADF103814. The objective is to assess clinical efficacy and safety of long term (up to 3 years) adefovir dipivoxil 10mg therapy.